Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Recommendations on treating multiple myeloma patients during the pandemic

ecancer COVID-19 Resources

Published: 6 Nov 2020

Views: 1083

Rating:

Save

Dr Jens Hillengass - Roswell Park Comprehensive Cancer Center, Buffalo, USA

Dr Jens Hillengass speaks to ecancer about his experience in treating multiple myeloma patients during the COVID-19 pandemic. He says that the treatment of cancer patients cannot be stopped just because of a pandemic, otherwise the patients will suffer greatly. He further gives recommendations on how doctors can treat multiple myeloma patients during these hard times.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related Videos

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM

Dr Elias Mai - Heidelberg University, Heidelberg, Germany

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM ( Dr Elias Mai - Heidelberg University, Heidelberg, Germany )

Multiple myeloma In Rwanda: The need for further research

Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda

Multiple myeloma In Rwanda: The need for further research ( Dr Eulade Rugengamanzi - Butaro Hospital, Ministry of Health, Rwanda )

Perspectives on advance care planning for advanced cancer in the Philippines

Dr Sachiko Estreller - Cordillera Hospital of the Divine Grace, Benguet, Philippines

Perspectives on advance care planning for advanced cancer in the Philippines ( Dr Sachiko Estreller - Cordillera Hospital of the Divine Grace, Benguet, Philippines )

A patient-reported questionnaire may eliminate the need for an ophthalmic exam before belantamab mafodotin dosing in TI NDMM

Prof Evangelos Terpos - University of Athens, School of Medicine, Athens, Greece

A patient-reported questionnaire may eliminate the need for an ophthalmic exam before belantamab mafodotin dosing in TI NDMM ( Prof Evangelos Terpos - University of Athens, School of Medicine, Athens, Greece )

OncoAlert Round Up for August 25th - 31st, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert Round Up for August 25th - 31st, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

Latest in immunological technologies that can treat, control, and prevent cancer

Dr Jill O’Donnell-Tormey - Chief Executive Officer, Cancer Research Institute

Latest in immunological technologies that can treat, control, and prevent cancer ( Dr Jill O’Donnell-Tormey - Chief Executive Officer, Cancer Research Institute )

The iCCaRE Consortium for Black Men - Addressing the disproportionate burden of prostate cancer

Mr Arnold Merriweather, Dr Che Ngufor and Dr Folakemi Odedina

The iCCaRE Consortium for Black Men - Addressing the disproportionate burden of prostate cancer ( Mr Arnold Merriweather, Dr Che Ngufor and Dr Folakemi Odedina )

War in Ukraine: The impacts and challenges the Polish cancer care system has faced

Prof Jacek Jassem - Medical University of Gdańsk, Gdańsk, Poland

War in Ukraine: The impacts and challenges the Polish cancer care system has faced ( Prof Jacek Jassem - Medical University of Gdańsk, Gdańsk, Poland )

ALLO-316 demonstrates encouraging anti-tumour activity for patients with advanced or metastatic ccRCC

Dr Samer Srour - The University of Texas MD Anderson Cancer Center, Houston, USA

ALLO-316 demonstrates encouraging anti-tumour activity for patients with advanced or metastatic ccRCC ( Dr Samer Srour - The University of Texas MD Anderson Cancer Center, Houston, USA )

More from ecancer